Search - tctmd.com

Displaying 21 - 40 of 52

Sort: Relevancy | Date

News Features

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

L.A. McKeown

December 24, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Daily News

One in Two Americans Have Cardiovascular Disease: AHA Stats

Michael O'Riordan

February 04, 2019

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Caitlin E. Cox

January 29, 2019

News Daily News

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

Michael O'Riordan

November 26, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News Daily News

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Michael O'Riordan

July 06, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

Advertisement

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Microvascular Disease Quadruples Risk of Leg Amputation

One in Two Americans Have Cardiovascular Disease: AHA Stats

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content